Biobanking and Biovalidation Core

NIH RePORTER · NIH · P20 · $246,588 · view on reporter.nih.gov ↗

Abstract

ABSTRACT - Biobanking and Biomarker Validation (BBV) Core The overall objective of the “Kansas Institute for Precision Medicine” (KIPM) COBRE Center at the University of Kansas Medical Center (KUMC) is to advance the customization of healthcare through promoting innovative scientific discoveries. We have entered the era of Precision Medicine, an initiative recently announced as part of the 21st Century Cures Act, which is focused on using the molecular basis of diseases to better match patients with the appropriate therapies and care resulting in improved outcomes. To advance this mission, we have established the Biobanking and Biomarker Validation (BBV) Core, which combines exceptional expertise and expands essential resources within established infrastructure, i.e., Biobanking - Biospecimen Repository Core Facility (BRCF) and Biomarker Validation - Biomarker Discovery Laboratory (BDL). Access to the BBV core will strengthen the biomedical research capacity of our COBRE Research Project Leaders (RPLs) and Pilot Project Leaders (PPLs) by enhancing their research base and infrastructure capacities. To advance precision medicine research within this Phase 2 COBRE program, the BBV core will 1) expand the services and infrastructure offered by the BBV Core; 2) build a business strategy for the BBV Core that contributes to its long-term sustainability; and 3) facilitate the competitiveness of KIPM COBRE RPLs and other faculty in securing external funding. The BBV core is designed to centralize these essential services that will in turn provide support to the KIPM COBRE faculty, pilot grantees, and researchers within our region and beyond. Given the level of sophistication of the materials and services required for the range of studies proposed within the KIPM COBRE, a highly integrated BBV core is not only cost effective but an absolute necessity. The BBV core eliminates redundant infrastructure and expense required for each researcher to develop their own capabilities or to search for the necessary research expertise. The BBV core will enable multiple COBRE RPLs and future pilot grantees, access to state- of-the-art facilities and laboratory expertise, thereby further reducing the relative cost of their studies. Furthermore, the BBV core will continue to provide in-kind technical staff-support and biobanking services, which help the KIPM COBRE faculty to utilize their available funding more effectively, both institutional startup and KIPM COBRE support. However, to remain sustainable the BBV Core will implement additional plans, including an operational business strategy, to ensure its longevity persists. The success of the BBV core and ultimately the COBRE faculty is essential to advancing the mission of the KIPM to advance the customization of healthcare through promoting innovative scientific discoveries.

Key facts

NIH application ID
10849363
Project number
2P20GM130423-06
Recipient
UNIVERSITY OF KANSAS MEDICAL CENTER
Principal Investigator
ANDREW K. GODWIN
Activity code
P20
Funding institute
NIH
Fiscal year
2024
Award amount
$246,588
Award type
2
Project period
2019-02-15 → 2029-03-31